A Post-market Prospective Clinical Study of Eurosilicone Luna Mammary Implants
A Prospective, Multi-centre, Observational, Non-comparative, Post-marketing Surveillance Study to Obtain Clinical Outcome Data on the Eurosilicone LunaXT Range of Silicone Breast Implants When Used in Breast Implantation.
調査の概要
状態
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:GCA Clinical affairs department
- 電話番号:+33 783326098
- メール:luna10PMCF@gcaesthetics.com
研究場所
-
-
-
Barcelona、スペイン
- 募集
- DScultp Clinic
-
コンタクト:
- Dr David Sanz
- メール:administracion@plasticabarcelona.com
-
主任研究者:
- David Sanz
-
-
-
-
-
Villefranche-sur-Saône、フランス
- 募集
- Dr Guillaume Lasserre
-
コンタクト:
- Dr Guillaume Lasserre
- メール:dr.lasserre.guillaume@orange.fr
-
主任研究者:
- Guillaume Lasserre
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- The target population includes subjects undergoing augmentation or reconstructive breast implant surgery in which the Eurosilicone Luna mammary implant is recommended.
Inclusion criteria are:
- Genetic female subjects aged between 18 and 65 years old.
- Subjects who underwent single or bilateral breast implantation with the study device for one of the following reasons:
i. Primary breast reconstruction following mastectomy (both for one-stage or two-stage surgeries, including patients with previous radiotherapy and who have ADMs (synthetic or natural).
ii. Primary breast augmentation (cosmetic surgery) with or without mastopexy iii. Breast revision surgery with or without mastopexy c) Subjects who have received a Eurosilicone Luna implant. d) Subjects who have provided informed consent and can adhere to the requirements of follow-up appointments as per the study protocol.
Exclusion criteria are:
- Subjects with a BMI >35.
- Subjects with autoimmune disease, lung fibrocystic disease, conditions that interfere with wound healing and blood clotting, a weakened immune system, reduced blood supply to the breast tissue or any other condition for which breast implants are contraindicated.
- Subjects who have participated in a clinical study which involve chemical or drug study within 3 months prior to surgery, with the exception of subjects who are participating in breast cancer-related clinical studies.
- Subjects with insufficient tissue covering due to either radiation damage on the chest wall, tight thoracic skin grafts or radical resection of the pectoralis major muscle.
- Subjects who, in the Investigator's clinical opinion, have existing local or metastatic carcinoma of the breast that is unlikely to be fully excised at the time of insertion of the breast implant.
- Subjects with known previous history of a sensitivity to silicone who, in the opinion of the Investigator, are unsuitable for surgery.
- Subjects with an active infection who are unsuitable for surgery unless, in the opinion of the investigator, they are treated and cleared by the investigator.
- Subjects with a history of abscesses anywhere in the body who, in the opinion of the Investigator, are unsuitable for surgery.
- Subjects with a known history of compromised wound healing.
- Subjects who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this study.
- Women who are pregnant and/or current breast feeders who do not stop breast feeding within 3 months of getting breast implants.
- Patients who have local recurrence or metastatic carcinoma at the time of insertion of breast implant.
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Aesthetic indications
Primary or revision breast augmentation with or without mastopexy.
|
The procedure is carried out at the surgeon's discretion.
This includes the incision location, the implant placement, the intraoperative applications.
他の名前:
|
|
Medical indications
Primary or revision of breast reconstruction.
Immediate or delayed reconstruction.
With or without associated chemotherapy and/or radiotherapy.
|
The procedure is carried out at the surgeon's discretion.
This includes the incision location, the implant placement, the intraoperative applications.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Frequency and rate of implant rupture
時間枠:10 years
|
10 years
|
|
Frequency and rate of capsular contracture Baker III-IV
時間枠:10 years
|
10 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Rate of the secondary surgical procedures required for correction of complications
時間枠:10 years
|
10 years
|
|
|
Patient satisfaction
時間枠:10 years
|
This will be determined using a questionnaire assessing the qualify of life.
|
10 years
|
|
Rate and frequency of local complications
時間枠:10 years
|
These complications may be related to the device itself or to the surgical procedure:
|
10 years
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- CLA-0007
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。